J&J inks 'first of its kind' pact with Singapore government to boost regional life sciences innovation

2023-09-26
J&J inks 'first of its kind' pact with Singapore government to boost regional life sciences innovation
Preview
来源: FierceBiotech
J&J's JLABS will work with local partners in Singapore to foster employment and commercialization opportunities.
Johnson & Johnson has inked a collaboration with the Singapore Economic Development Board to boost life sciences innovation in the region, touting the pact as the “first of its kind.”
Under the new partnership, Johnson & Johnson’s incubator—dubbed JLABS—will help early-stage companies in Singapore develop their discoveries into medicines, medical technologies and healthcare solutions. JLABS will also work with local partners regarding venture and talent offerings to foster employment and commercialization opportunities.
The pact demonstrates J&J’s commitment to advancing science and technology in the Asia Pacific region to address global needs, the Big Pharma's Chief External Innovation and Medical Officer William Hait, M.D., Ph.D., said in the Sept. 26 release.
JLABs and the country's Economic Development Board are set to host a symposium in Singapore before the year ends and share “subsequent announcements” that have emerged from the new collaboration.
The deal comes as the city-state continues work to become a biotech hub—efforts that launched way back in 2000 when the government made biomedical research the “fourth pillar” of the economy. The billions of dollars pumped into the life sciences sector over the next 20 years have resulted in a few notable success stories, including Chugai's decision to set up a research institute and GSK's antibiotic and vaccine manufacturing plants.
Singapore itself isn’t a huge commercial market—or at least not a prime destination for launching a drug. But Singapore as a biopharma manufacturing hub makes sense because of the large market surrounding it, Stephen Sunderland, head of L.E.K.’s Southeast Asia healthcare and life science practice based in Singapore, told Fierce last month.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路,让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。